Differentiated thyroid cancer - Personalized therapies to prevent overtreatment

Nature Reviews Endocrinology

Volumn 10, Issue 9, 2014, Pages 563-574

  Luster, Markus ^a   Weber, Theresia ^b   Verburg, Frederik A ^c  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IODINE 131; LEVOTHYROXINE; MULTITARGETED KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; RECOMBINANT THYROTROPIN; SELUMETINIB; UNCLASSIFIED DRUG;

CANCER SURGERY; DIFFERENTIATED THYROID CANCER; DOSIMETRY; FOLLOW UP; HUMAN; HYPOCALCEMIA; HYPOTHYROIDISM; LARYNGEAL NERVE INJURY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW;

HUMANS; INDIVIDUALIZED MEDICINE; IODINE RADIOISOTOPES; MOLECULAR TARGETED THERAPY; RECURRENT LARYNGEAL NERVE INJURIES; THYROID NEOPLASMS; THYROIDECTOMY; THYROXINE;

EID: 84906790053     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2014.100     Document Type: Review

References (148)

1. Lee, T. J., Kim, S., Cho, H. J. & Lee, J. H. The incidence of thyroid cancer is affected by the characteristics of a healthcare system. J. Korean Med. Sci. 27, 1491-1498 (2012).
2. Udelsman, R. & Zhang, Y. The epidemic of thyroid cancer in the United States: the role of endocrinologists and ultrasounds. Thyroid 24, 472-479 (2014).
3. Chen, A. Y., Jemal, A. & Ward, E. M. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 115, 3801-3807 (2009).
4. Biermann, M. et al. Multicenter study differentiated thyroid carcinoma (MSDS). Diminished acceptance of adjuvant external beam radiotherapy. Nuklearmedizin 42, 244-250 (2003). (Pubitemid 38101133)
5. Haymart, M. R. et al. Variation in the management of thyroid cancer. J. Clin. Endocrinol. Metab. 98, 2001-2008 (2013).
6. Banach, R. et al. Results of the Thyroid Cancer Alliance international patient/survivor survey: psychosocial/informational support needs, treatment side effects and international differences in care. Hormones (Athens) 12, 428-438 (2013).
7. Alexander, E. K. et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N. Engl. J. Med. 367, 705-715 (2012).
8. 99mTc-methoxyisobutylisonitrile scintigraphy and fine-needle aspiration cytology offers an accurate and potentially cost-effective investigative strategy for the assessment of solitary or dominant thyroid nodules. Eur. J. Nucl. Med. Mol. Imaging 41, 105-115 (2014).
9. Verburg, F. A. et al. Life expectancy is reduced in differentiated thyroid cancer patients ≥45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J. Clin. Endocrinol. Metab. 98, 172-180 (2013).
10. Links, T. P. et al. Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr. Relat. Cancer 12, 273-280 (2005). (Pubitemid 40896446)
11. Vrachimis, A., Riemann, B., Gerss, J., Maier, T. & Schober, O. Peace of mind for patients with differentiated thyroid cancer? Nuklearmedizin 52, 115-120 (2013).
12. Ito, K. et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 24, 27-34 (2014).
13. 18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J. Clin. Endocrinol. Metab. 91, 498-505 (2006). (Pubitemid 43236915)
14. Miyauchi, A. et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid 21, 707-716 (2011).
15. Cooper, D. S. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167-1214 (2009).
16. Pacini, F. et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 154, 787-803 (2006). (Pubitemid 43997716)
17. Pacini, F., Castagna, M. G., Brilli, L. & Pentheroudakis, G. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21 (Suppl. 5), v214-v219 (2010).
18. Bilimoria, K. Y. et al. Extent of surgery affects survival for papillary thyroid cancer. Ann. Surg. 246, 375-381 (2007). (Pubitemid 47312122)
19. Barney, B. M., Hitchcock, Y. J., Sharma, P., Shrieve, D. C. & Tward, J. D. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck 33, 645-649 (2011).
20. Haigh, P. I., Urbach, D. R. & Rotstein, L. E. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann. Surg. Oncol. 12, 81-89 (2005). (Pubitemid 40486645)
21. Mendelsohn, A. H., Elashoff, D. A., Abemayor, E. & St John, M. A. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch. Otolaryngol. Head Neck Surg. 136, 1055-1061 (2010).
22. Matsuzu, K. et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J. Surg. 38, 68-79 (2014).
23. Ito, Y. et al. Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up. World J. Surg. 36, 1274-1278 (2012).
24. Pereira, J. A. et al. Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery 138, 1095-1100 (2005).
25. Grogan, R. H. et al. A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up. Surgery 154, 1436-1446 (2013).
26. Barczynski, M., Konturek, A., Stopa, M. & Nowak, W. Nodal recurrence in the lateral neck after total thyroidectomy with prophylactic central neck dissection for papillary thyroid cancer. Langenbecks Arch. Surg. 399, 237-244 (2013).
27. Kruijff, S. et al. Patterns of structural recurrence in papillary thyroid cancer. World J. Surg. 38, 653-659 (2014).
28. Wang, T. S., Cheung, K., Farrokhyar, F., Roman, S. A. & Sosa, J. A. A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer. Ann. Surg. Oncol. 20, 3477-3483 (2013).
29. Lundgren, C. I., Hall, P., Dickman, P. W. & Zedenius, J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer 106, 524-531 (2006). (Pubitemid 43157614)
30. Zaydfudim, V., Feurer, I. D., Griffin, M. R. & Phay, J. E. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery 144, 1070-1077 (2008).
31. Enyioha, C., Roman, S. A. & Sosa, J. A. Central lymph node dissection in patients with papillary thyroid cancer: a population level analysis of 14,257 cases. Am. J. Surg. 205, 655-661 (2013).
32. Chisholm, E. J., Kulinskaya, E. & Tolley, N. S. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope 119, 1135-1139 (2009).
33. Shan, C. X. et al. Routine central neck dissection in differentiated thyroid carcinoma: a systematic review and meta-analysis. Laryngoscope 122, 797-804 (2012).
34. Zhu, W., Zhong, M. & Ai, Z. Systematic evaluation of prophylactic neck dissection for the treatment of papillary thyroid carcinoma. Jpn J. Clin. Oncol. 43, 883-888 (2013).
35. Zetoune, T. et al. Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis. Ann. Surg. Oncol. 17, 3287-3293 (2010).
36. Zanocco, K., Elaraj, D. & Sturgeon, C. Routine prophylactic central neck dissection for low-risk papillary thyroid cancer: a cost-effectiveness analysis. Surgery 154, 1148-1155 (2013).
37. Carling, T. et al. American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid 22, 237-244 (2012).
38. Dultz, L. A. et al. Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer. Surgery 154, 1239-1244 (2013).
39. Stack, B. C. Jr et al. American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer. Thyroid 22, 501-508 (2012).
40. Dralle, H. et al. Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgery. Surgery 136, 1310-1322 (2004). (Pubitemid 39647550)
41. Dralle, H., Sekulla, C., Lorenz, K., Brauckhoff, M. & Machens, A. Intraoperative monitoring of the recurrent laryngeal nerve in thyroid surgery. World J. Surg. 32, 1358-1366 (2008).
42. Phelan, E. et al. Continuous vagal IONM prevents RLN paralysis by revealing initial EMG changes of impending neuropraxic injury: a prospective, multicenter study. Laryngoscope 124, 1498-1505 (2014).
43. Loch-Wilkinson, T. J. et al. Nerve stimulation in thyroid surgery: is it really useful? ANZ J. Surg. 77, 377-380 (2007). (Pubitemid 46709718)
44. Barczynski, M. et al. External branch of the superior laryngeal nerve monitoring during thyroid and parathyroid surgery: International Neural Monitoring Study Group standards guideline statement. Laryngoscope 123 (Suppl. 4), S1-S14 (2013).
45. Arlt, W. et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur. J. Endocrinol. 146, 215-222 (2002). (Pubitemid 34162914)
46. Bohrer, T., Pasteur, I., Lyutkevych, O., Fleischmann, P. & Tronko, M. Permanent hypoparathyroidism due to thyroid cancer surgical procedures in patients exposed to radiation in the Chernobyl, Ukraine, nuclear reactor accident. [German]. Dtsch Med. Wochenschr. 130, 2501-2506 (2005). (Pubitemid 41639583)
47. Thomusch, O. et al. Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: prospective multicenter study in Germany. World J. Surg. 24, 1335-1341 (2000).
48. McHenry, C. R., Speroff, T., Wentworth, D. & Murphy, T. Risk factors for post-thyroidectomy hypocalcemia. Surgery 116, 641-647 (1994).
49. Wingert, D. J. et al. Post-thyroidectomy hypocalcemia. Incidence and risk factors. Am. J. Surg. 152, 606-610 (1986). (Pubitemid 17199195)
50. Paek, S. H. et al. Risk factors of hypoparathyroidism following total thyroidectomy for thyroid cancer. World J. Surg. 37, 94-101 (2013).
51. Bozec, A. et al. Clinical impact of cervical lymph node involvement and central neck dissection in patients with papillary thyroid carcinoma: a retrospective analysis of 368 cases. Eur. Arch. Otorhinolaryngol. 268, 1205-1212 (2011).
52. Cavicchi, O. et al. Transient hypoparathyroidism following thyroidectomy: a prospective study and multivariate analysis of 604 consecutive patients. Otolaryngol. Head Neck Surg. 137, 654-658 (2007). (Pubitemid 47445879)
53. Demidchik, Y. E. et al. Comprehensive clinical assessment of 740 cases of surgically treated thyroid cancer in children of Belarus. Ann. Surg. 243, 525-532 (2006).
54. van Santen, H. M. et al. Frequent adverse events after treatment for childhood-onset differentiated thyroid carcinoma: a single institute experience. Eur. J. Cancer 40, 1743-1751 (2004). (Pubitemid 38902911)
55. Henry, J. F. et al. Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch. Surg. 383, 167-169 (1998). (Pubitemid 28442533)
56. Cayo, A. K. et al. Predicting the need for calcium and calcitriol supplementation after total thyroidectomy: results of a prospective, randomized study. Surgery 152, 1059-1067 (2012).
57. Seidlin, S. M., Marinelli, L. D. & Oshry, E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. JAMA 132, 838-847 (1946).
58. - symporter. Mechanism, stoichiometry, and specificity. J. Biol. Chem. 272, 27230-27238 (1997).
59. Mazzaferri, E. L. & Jhiang, S. M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 97, 418-428 (1994). (Pubitemid 24345593)
60. Verburg, F. A., de Keizer, B., Lips, C. J., Zelissen, P. M. & de Klerk, J. M. Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur. J. Endocrinol. 152, 33-37 (2005). (Pubitemid 40185450)
61. Mazzaferri, E. L. & Kloos, R. T. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J. Clin. Endocrinol. Metab. 86, 1447-1463 (2001). (Pubitemid 32374886)
62. Tubiana, M. et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 55, 794-804 (1985). (Pubitemid 15173518)
63. Simpson, W. J., Panzarella, T., Carruthers, J. S., Gospodarowicz, M. K. & Sutcliffe, S. B. Papillary and follicular thyroid cancer: impact of treatment in 1,578 patients. Int. J. Radiat. Oncol. Biol. Phys. 14, 1063-1075 (1988).
64. Schlumberger, M. J. Papillary and follicular thyroid carcinoma. N. Engl. J. Med. 338, 297-306 (1998). (Pubitemid 28065257)
65. Utiger, R. D. Follow-up of patients with thyroid carcinoma. N. Engl. J. Med. 337, 928-930 (1997). (Pubitemid 27408578)
66. Shattuck, T. M., Westra, W. H., Ladenson, P. W. & Arnold, A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N. Engl. J. Med. 352, 2406-2412 (2005). (Pubitemid 40958437)
67. Verburg, F. A., Dietlein, M., Lassmann, M., Luster, M. & Reiners, C. Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 36, 343-346 (2009).
68. Sherman, S. I., Tielens, E. T., Sostre, S., Wharam, M. D. Jr & Ladenson, P. W. Clinical utility of post-treatment radioiodine scans in the management of patients with thyroid carcinoma. J. Clin. Endocrinol. Metab. 78, 629-634 (1994). (Pubitemid 24083303)
69. Tenenbaum, F., Corone, C., Schlumberger, M. & Parmentier, C. Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease. Eur. J. Cancer 32A, 1262 (1996). (Pubitemid 126783095)
70. DeGroot, L. J., Kaplan, E. L., Shukla, M. S., Salti, G. & Straus, F. H. Morbidity and mortality in follicular thyroid cancer. J. Clin. Endocrinol. Metab. 80, 2946-2953 (1995).
71. Samaan, N. A. et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1,599 patients. J. Clin. Endocrinol. Metab. 75, 714-720 (1992).
72. Sawka, A. M. et al. Clinical review 170: a systematic review and meta-analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 89, 3668-3676 (2004). (Pubitemid 39089119)
73. (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur. J. Endocrinol. 153, 651-659 (2005). (Pubitemid 41672411)
74. Rosario, P. W. et al. Is adjuvant therapy useful in patients with papillary carcinoma smaller than 2 cm? Thyroid 17, 1225-1228 (2007).
75. Durante, C. et al. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? J. Clin. Endocrinol. Metab. 97, 2748-2753 (2012).
76. Nascimento, C. et al. Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation. Eur. J. Endocrinol. 169, 689-693 (2013).
77. 131I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging 37, 276-283 (2010).
78. Mazzaferri, E. L. & Kloos, R. T. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J. Clin. Endocrinol. Metab. 87, 1490-1498 (2002). (Pubitemid 34615227)
79. Mallick, U., Harmer, C., Hackshaw, A. & Moss, L. Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo. Clin. Oncol. (R. Coll. Radiol.) 24, 159-161 (2012).
80. Edmonds, C. J., Hayes, S., Kermode, J. C. & Thompson, B. D. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br. J. Radiol. 50, 799-807 (1977). (Pubitemid 8212220)
81. Bal, C. S., Kumar, A. & Pant, G. S. Radioiodine lobar ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer. Nucl. Med. Commun. 24, 203-208 (2003).
82. Luster, M. et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging 35, 1941-1959 (2008).
83. Reiners, C. & Demidchik, Y. E. Differentiated thyroid cancer in childhood: pathology, diagnosis, therapy. Pediatr. Endocrinol. Rev. 1 (Suppl. 2), 230-235 (2003).
84. Reiners, C. et al. Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very-high-risk radiation-induced differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 98, 3039-3048 (2013).
85. 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level. Eur. J. Nucl. Med. Mol. Imaging 38, 1296-1302 (2011).
86. Doi, S. A., Woodhouse, N. J., Thalib, L. & Onitilo, A. Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited. Clin. Med. Res. 5, 87-90 (2007).
87. Cheng, W. et al. Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis. J. Clin. Endocrinol. Metab. 98, 1353-1360 (2013).
88. 131I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 77, 2574-2580 (1996).
89. 131I dose in differentiated thyroid cancer. Clin. Endocrinol. (Oxf.) 52, 765-773 (2000). (Pubitemid 30409270)
90. 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J. Clin. Endocrinol. Metab. 92, 28-38 (2007). (Pubitemid 46075005)
91. Mallick, U. et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N. Engl. J. Med. 366, 1674-1685 (2012).
92. Schlumberger, M. et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N. Engl. J. Med. 366, 1663-1673 (2012).
93. Lassmann, M., Reiners, C. & Luster, M. Dosimetry and thyroid cancer: the individual dosage of radioiodine. Endocr. Relat. Cancer 17, R161-R172 (2010).
94. Lassmann, M., Hanscheid, H., Verburg, F. A. & Luster, M. The use of dosimetry in the treatment of differentiated thyroid cancer. Q. J. Nucl. Med. Mol. Imaging 55, 107-115 (2011).
95. Reiners, C., Hanscheid, H., Luster, M., Lassmann, M. & Verburg, F. A. Radioiodine for remnant ablation and therapy of metastatic disease. Nat. Rev. Endocrinol. 7, 589-595 (2011).
96. Lassmann, M. et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur. J. Nucl. Med. Mol. Imaging 35, 1405-1412 (2008).
97. 131I activity in thyroid cancer patients. Eur. J. Nucl. Med. Mol. Imaging 38, 673-680 (2011).
98. 131I for therapy of differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 96, 3217-3225 (2011).
99. 131I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. J. Clin. Endocrinol. Metab. 98, 2693-2700 (2013).
100. Castagna, M. G. et al. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. Eur. J. Endocrinol. 169, 23-29 (2013).
101. Luster, M., Felbinger, R., Dietlein, M. & Reiners, C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 15, 1147-1155 (2005). (Pubitemid 41720721)
102. Dow, K. H., Ferrell, B. R. & Anello, C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 7, 613-619 (1997). (Pubitemid 27371801)
103. Schroeder, P. R. et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J. Clin. Endocrinol. Metab. 91, 878-884 (2006). (Pubitemid 43357753)
104. Hanscheid, H. et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J. Nucl. Med. 47, 654 (2006).
105. Rosario, P. W., Borges, M. A. & Purisch, S. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J. Nucl. Med. 49, 1776-1782 (2008).
106. Frigo, A. et al. Chromosome translocation frequency after radioiodine thyroid remnant ablation: a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawal. J. Clin. Endocrinol. Metab. 94, 3472-3476 (2009).
107. Haugen, B. R. et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J. Clin. Endocrinol. Metab. 84, 3877-3885 (1999). (Pubitemid 30644169)
108. Borget, I. et al. Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur. J. Nucl. Med. Mol. Imaging 35, 1457-1463 (2008).
109. Borget, I. et al. Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with thyrogen and thyroid hormone withdrawal. Eur. J. Endocrinol. 156, 531-538 (2007). (Pubitemid 46796519)
110. Luster, M. et al. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 85, 3640-3645 (2000).
111. de Keizer, B. et al. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. Eur. J. Nucl. Med. Mol. Imaging 30, 367-373 (2003). (Pubitemid 36692861)
112. Robbins, R. J., Driedger, A. & Magner, J. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 16, 1121-1130 (2006). (Pubitemid 44864487)
113. Bohuslavizki, K. H. et al. Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial. Cancer Biother. Radiopharm. 14, 337-347 (1999). (Pubitemid 29483435)
114. Kim, S. J. et al. Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients: analysis of quantitative salivary scan. Thyroid 18, 325-331 (2008).
115. Jentzen, W. et al. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging. Eur. J. Nucl. Med. Mol. Imaging 37, 2298-2306 (2010).
116. Nakada, K. et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J. Nucl. Med. 46, 261-266 (2005). (Pubitemid 43073433)
117. Verburg, F. A., Mader, U., Kruitwagen, C. L., Luster, M. & Reiners, C. A comparison of prognostic classification systems for differentiated thyroid carcinoma. Clin. Endocrinol. (Oxf.) 72, 830-838 (2010).
118. Brierley, J. D., Panzarella, T., Tsang, R. W., Gospodarowicz, M. K. & O'Sullivan, B. A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer 79, 2414-2423 (1997). (Pubitemid 27251027)
119. Tuttle, R. M. et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20, 1341-1349 (2010).
120. Blum, M., Tiu, S., Chu, M., Goel, S. & Friedman, K. I-131 SPECT/CT elucidates cryptic findings on planar whole-body scans and can reduce needless therapy with I-131 in post-thyroidectomy thyroid cancer patients. Thyroid 21, 1235-1247 (2011).
121. Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B. & Vanderpump, M. P. J. 2012 ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur. Thyroid J. 1, 55-71 (2012).
122. McLeod, D. S. et al. Prognosis of differentiated thyroid cancer in relation to serum TSH and thyroglobulin antibody status at time of diagnosis. Thyroid 24, 35-42 (2014).
123. Smit, J. W. et al. Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study. J. Clin. Endocrinol. Metab. 90, 6041-6047 (2005). (Pubitemid 41606523)
124. Selmer, C. et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ 345, e7895 (2012).
125. Hovens, G. C. et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 92, 2610-2615 (2007). (Pubitemid 47037365)
126. Cooper, D. S. et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8, 737-744 (1998). (Pubitemid 28535681)
127. Diessl, S. et al. Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma. Clin. Endocrinol. (Oxf.) 76, 586-592 (2012).
128. Sherman, S. I. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin. Oncol. (R. Coll. Radiol.) 22, 464-468 (2010).
129. Nikiforov, Y. E. & Nikiforova, M. N. Molecular genetics and diagnosis of thyroid cancer. Nat. Rev. Endocrinol. 7, 569-580 (2011).
130. Elisei, R. et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J. Clin. Endocrinol. Metab. 93, 3943-3949 (2008).
131. Sarne, D. H. A piece of the puzzle: what does BRAF status mean in the management of patients with papillary thyroid carcinoma? J. Clin. Endocrinol. Metab. 97, 3094-3096 (2012).
132. Simon, D. et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur. J. Nucl. Med. Mol. Imaging 29, 775-782 (2002).
133. Handkiewicz-Junak, D. et al. 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study. Thyroid Res. 2, 8 (2009).
134. Short, S. C., Suovuori, A., Cook, G., Vivian, G. & Harmer, C. A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin. Oncol. (R. Coll. Radiol.) 16, 569-574 (2004). (Pubitemid 39517666)
135. Liu, Y. Y. et al. Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma. Clin. Endocrinol. (Oxf.) 68, 605-609 (2008). (Pubitemid 351388717)
136. Liu, Y. Y. et al. Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. Eur. J. Endocrinol. 154, 525-531 (2006).
137. Tepmongkol, S., Keelawat, S., Honsawek, S. & Ruangvejvorachai, P. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-?. Thyroid 18, 697-704 (2008). (Pubitemid 352009939)
138. 124I PET/CT imaging. Clin. Nucl. Med. 37, e47-e52 (2012).
139. Kebebew, E. et al. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. Thyroid 19, 953-956 (2009).
140. Rosenbaum-Krumme, S. J., Bockisch, A. & Nagarajah, J. Pioglitazone therapy in progressive differentiated thyroid carcinoma. Nuklearmedizin 51, 111-115 (2012).
141. Ho, A. L. et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N. Engl. J. Med. 368, 623-632 (2013).
142. Hoftijzer, H. et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur. J. Endocrinol. 161, 923-931 (2009).
143. Kim, K. B. et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid 23, 1277-1283 (2013).
144. Dadu, R. et al. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J. Clin. Endocrinol. Metab. 99, 2086-2094 (2014).
145. Lim, S. M. et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann. Oncol. 24, 3089-3096 (2013).
146. Pacini, F. et al. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Exp. Rev. Endocrinol. Metab. 7, 541-554 (2012).
147. Versari, A. et al. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients. Thyroid 24, 715-726 (2014).
148. Ross, D. S. & Tuttle, R. M. Observing micopapillary thyroid cancers. Thyroid 24, 3-6 (2014).